Gilead Sciences | GILD - Pendapatan Penjualan





Penjualan Perubahan Tanggal
AbbVie USD 17.4B 410M 2026-09
Agios Pharmaceuticals USD 44.74M 25.94M 2026-06
ALKERMES USD 496.01M 103.1M 2026-06
Alnylam Pharmaceuticals USD 1.46B 170M 2026-09
Amgen USD 10.1B 1.48B 2026-06
Biogen USD 2.8B 60M 2026-09
BioMarin Pharmaceutical USD 990M 224M 2026-06
Bristol-Myers Squibb USD 13.07B 100M 2026-09
Coherus Biosciences USD 12.75M 1.18M 2025-12
Eli Lilly USD 24.4B 1.43B 2026-09
Gilead Sciences USD 8.3B 500M 2026-09
GlaxoSmithKline GBP 8.89B 480M 2026-09
Glaxosmithkline GBP 10.09B 1.37B 2026-03
Incyte USD 1.56B 110M 2026-09
J&J USD 25.4B 89M 2026-09
Merck USD 18.1B 1.5B 2026-09
Moderna USD 100M 289M 2026-06
Neurocrine Biosciences USD 959M 148M 2026-06
Novartis USD 14.52B 112M 2026-09
Pfizer USD 15.03B 530M 2026-06
PTC Therapeutics USD 357.8M 3.2M 2026-09
Puma Biotechnology USD 80.54M 33.46M 2024-09
Regeneron Pharmaceuticals USD 5.12B 830M 2026-09
Sangamo BioSciences USD 356K 125K 2024-06
Sanofi EUR 14.44B 2.49B 2026-09
Sarepta Therapeutics USD 401.3M 329.5M 2026-06
United Therapeutics USD 783.3M 1.8M 2026-06
Vertex Pharmaceuticals USD 3.33B 340M 2026-06